Investors & Media
Medical Affairs
Contact

Investors & Media

At Vera Therapeutics, our mission is to pursue truth in science to transform medicine in autoimmune diseases, starting with kidney disease.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

View more

Corporate Presentation

Download

Latest Press Releases

Oct 2, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Sep 15, 2026

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Events & Presentations

Sep 15, 2026 5:35 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Sep 10, 2026 8:00 AM EDT

Cantor Global Healthcare Conference 2026

Jul 7, 2026 4:30 AM EDT

Virtual Investor Event: TRUTAKNA Accelerated Approval

Contact

INVESTOR INQUIRIES

IR@veratx.com

MEDIA INQUIRIES

corporatecommunications@veratx.com

Leaving this site

The link will take you to a third-party site and is not owned or controlled by Vera. Vera makes no representation as to the accuracy of the information contained on third-party sites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.